tradingkey.logo
tradingkey.logo

Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1

ReutersMar 25, 2026 12:29 PM

Sarepta Therapeutics Inc SRPT.O:

  • SAREPTA ANNOUNCES FIRST CLINICAL DATA FROM SIRNA PIPELINE TARGETING FSHD1 AND DM1

  • SAREPTA THERAPEUTICS INC - SIRNA ACHIEVES HIGH MUSCLE CONCENTRATIONS WITHOUT DOSE LIMITING TOXICITY FOR FSHD1 AND DM1

  • SAREPTA THERAPEUTICS INC - PROOF-OF-CONCEPT DATA SHOW SINGLE DOSE OF SRP-1001 AND SRP-1003 REDUCES TARGET PROTEIN OR MRNA

  • SAREPTA THERAPEUTICS INC - MAJORITY OF ADVERSE EVENTS IN STUDIES WERE MILD TO MODERATE AND NOT DOSE DEPENDENT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI